Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2006

Separate Manufacturing Deals Inked at Cleveland BioLabs and Viron Therapeutics

  • Cleveland BioLabs (CBLI) and SynCo Bio Partners completed the transfer of technology in their joint effort to produce CBLI's lead product, Protectan CBLB502, and have signed an agreement to produce sufficient amounts for clinical trials and the commercial market.

    SynCo will work with CBLI to develop the manufacturing process, as well as manufacture CBLB502 for Phase I trials and commercial release.

    Viron Therapeutics signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing of VT-111. Under the agreement, Diosynth Biotechnology will support the process improvement, process development, and clinical product manufacturing.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »